Breast cancer treatment by adipose-derived stem cells: an experimental study.
Breast cancer is a leading cause of deaths in humans. Mesenchymal stem cells (MSC) have been identified to possess powerful therapeutic properties in humans. The capability of MSC to migrate toward injured tissue suggests their potential in new clinical applications. The aim of this study was to investigate the potential role of adipose stem cells (ADSCs) for recovering cellular potential and delaying or treating breast cancer in an animals model of human breast cancer. Cellular adoptive immunotherapy using adipose derived mesenchymal stem cells tailored made for Breast Cancer patients would offer a new effective less invasive treatment method. ADSCs injected into the cancer tumor did not affect tumor growth and the cancer kept growing. ADSCs injected so that they surrounded the tumor decreased growth and the tumor had disappeared after 3 to 8 weeks and total recovery was maintained throughout the 6 months of study. The adipose stem cells are the "active" and "regenerative" part of fat. ADSCs may appear promising for their use as "secretor" of the supernatant substance against breast cancer cells.
Center for Clinical Immunology HBRC-Human Biology Research Center in Nuclear Medicine and Biophysics Department and at the Sharett Institute of Oncology Research Center, University Hospital, Ein –Karem , Jerusalem, Israel
Yves-Gerard
YG
Illouz
D000273:Adipose Tissue / Q000166:cytology; D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D002454:Cell Differentiation / Q000235:genetics; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000276:immunology; D051379:Mice; D023041:Xenograft Model Antitumor Assays